In colon cancer, ARD1 has been demonstrated to acetylate Nrf2, thereby inhibiting its degradation via the proteasome pathway, further facilitating Nrf2 nuclear translocation, enhancing the transactivation of downstream target genes, and ultimately contributing to colon cancer cell proliferation and malignant phenotype 86. The gene discussed is NFE2L2; the disease is malignant colon neoplasm.